Drugs / EXLINKIBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05075993 | Nov 2021 → Feb 2027 expected | esophageal cancer, gastric cancer, head and neck carcinoma, hepatocellular carcinoma +4 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04694781 | May 2021 → Oct 2023 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 1 | NCT04130542 | Oct 2019 → Dec 2025 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05301764 | May 2022 → Dec 2025 | soft tissue sarcoma | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06378177 | Jun 2024 → Oct 2027 expected | head and neck squamous cell carcinoma | Lyvgen Biopharma Holdings Limited | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-07-01 | Lyvgen Biopharma Holdings Limited | Regulatory Dr. C. Hubert Chan, Chief Medical Officer of Lyvgen Biopharma: Innovation in Clinical Development for the Breakthrough Cancer Immunotherapy of Next-Generation IO Agonistic Antibodies lyvgen.com ↗
In addition, the combination of LVGN6051 and Anlotinib (VEGFR-TKI) for the treatment of sarcoma has been approved in China and the first-in-patient dosing is expected soon. |
| 2021-06-04 | Lyvgen Biopharma Holdings Limited | Results Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting lyvgen.com ↗
No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-04 | Lyvgen Biopharma Holdings Limited | LVGN6051 (exlinkibart) 4-1BB agonist two clinical studies selected for ASCO 2024 annual meeting lyvgen.com ↗ |
| 2022-07-01 | Lyvgen Biopharma Holdings Limited | Dr. C. Hubert Chan, Chief Medical Officer of Lyvgen Biopharma: Innovation in Clinical Development for the Breakthrough Cancer Immunotherapy of Next-Generation IO Agonistic Antibodies lyvgen.com ↗ |
| 2021-06-04 | Lyvgen Biopharma Holdings Limited | Lyvgen Biopharma Presents Clinical Trial Data of CD137/4-1BB Agonistic Antibody LVGN6051 at the 2021 ASCO Annual Meeting lyvgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXLINKIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314677 ↗ |
| Known as | LVGN6051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05075993 ↗ |
| Action | Activate | “acts as an agonist against CD137” NCT04130542 ↗ |
| Modality | Monoclonal antibody | “LVGN6051 is a humanized monoclonal antibody” NCT04130542 ↗ |
| Route | Intravenous | “Route of administration is IV infusion” NCT04130542 ↗ |